AI Analyzes Blood Sample "Bio-signature" To Identify Brain Cancer
Complete the form below to unlock access to ALL audio articles.
A blood test which could help to accelerate the diagnosis of brain cancer has been developed in research led at the University of Strathclyde.
The patented technology uses infrared light to produce a "bio-signature" of a blood sample and applies artificial intelligence to check for the signs of cancer.
Dr Matthew J. Baker led the study. He said: “This is the first publication of data from our clinical feasibility study and it is the first demonstration that our blood test works in the clinic. Earlier detection of brain tumors in the diagnostic pathway brings the potential to significantly improve patient quality of life and survival, whilst also providing savings to the health services.”
Dr Paul Brennan, a partner in the study, said: “Diagnosing brain tumors is difficult, leading to delays and frustration for lots of patients. The problem is that symptoms of brain tumor are quite non-specific, such as headache, or memory problems. It can be difficult for doctors to tell which people are most likely to have a brain tumor."
“With this new test, we have shown that we can help doctors quickly identify which patients with these non-specific symptoms should be prioritized for urgent brain imaging. This means a more rapid diagnosis for people with a brain tumor, and quicker access to treatment.”
Patients with brain cancer frequently present with non-specific symptoms and the final cancer diagnosis can be time-consuming. The researchers have analyzed samples from a prospective cohort of 104 patients, they found that the blood test could distinguish patients with brain cancer from healthy individuals correctly 87% of the time.
These findings suggest that this approach may be useful to doctors in helping to prioritize patients needing brain scans in order to diagnose tumors. While the proposed system does not offer an absolute diagnosis, it could play a significant role in the diagnostic process as a triage tool.
Reference
Butler et al. (2019). Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer. Nature Communications. DOI: https://doi.org/10.1038/s41467-019-12527-5
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
